Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs

Show full item record



Permalink

http://hdl.handle.net/10138/330805

Citation

Ottka , C , Weber , C , Mueller , E & Lohi , H 2021 , ' Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs ' , Metabolomics , vol. 17 , no. 6 , 54 . https://doi.org/10.1007/s11306-021-01803-5

Title: Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs
Author: Ottka, Claudia; Weber, Corinna; Mueller, Elisabeth; Lohi, Hannes
Other contributor: University of Helsinki, Veterinary Biosciences
University of Helsinki, Helsinki One Health (HOH)






Date: 2021-06
Language: eng
Number of pages: 11
Belongs to series: Metabolomics
ISSN: 1573-3882
DOI: https://doi.org/10.1007/s11306-021-01803-5
URI: http://hdl.handle.net/10138/330805
Abstract: Introduction Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures. In addition to its central nervous system (CNS) depressing effects, long-term phenobarbital administration affects liver function. However, broader metabolic consequences of phenobarbital treatment are poorly characterized. Objectives To identify metabolic changes in the sera of phenobarbital-treated dogs and to investigate the relationship between serum phenobarbital concentration and metabolite levels. Methods Leftovers of clinical samples were used: 58 cases with phenobarbital concentrations ranging from 7.8 mu g/mL to 50.8 mu g/mL, and 25 controls. The study design was cross-sectional. The samples were analyzed by a canine-specific H-1 NMR metabolomics platform. Differences between the case and control groups were evaluated by logistic regression. The linear relationship between metabolite and phenobarbital concentrations was evaluated using linear regression. Results Increasing concentrations of glycoprotein acetyls, LDL particle size, palmitic acid, and saturated fatty acids, and decreasing concentrations of albumin, glutamine, histidine, LDL particle concentration, multiple HDL measures, and polyunsaturated fatty acids increased the odds of the sample belonging to the phenobarbital-treated group, having a p-value <.0033, and area under the curve (AUC) > .7. Albumin and glycoprotein acetyls had the best discriminative ability between the groups (AUC: .94). No linear associations between phenobarbital and metabolite concentrations were observed. Conclusion The identified metabolites are known to associate with, for example, liver and CNS function, inflammatory processes and drug binding. The lack of a linear association to phenobarbital concentration suggests that other factors than the blood phenobarbital concentration contribute to the magnitude of metabolic changes.
Subject: Anticonvulsant
Epilepsy
Metabolism
Phenobarbital
Canine
FUNCTION-TESTS
FATTY-ACIDS
EPILEPSY
BIOMARKER
GLUTAMATE
GLYCA
GLYCOPROTEIN
ASSOCIATIONS
INFLAMMATION
EXPRESSION
413 Veterinary science
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Ottka2021_Artic ... MetabolomicsUncoversMu.pdf 975.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record